Ani Pharmaceuti Patent-Cliff Exposure & CMS Drug Spending Portfolio

Ani Pharmaceuti (US): 12 reconciled FDA prescription therapies, $203.7M 2024 CMS Part D & Medicaid spend, and $14,362 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies12
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$203.7M
2024 Medicare Part D Spend$155.0M
2024 Medicaid Spend$48.7M
California HCAI SB 17 FilingsSpecialty launch notice ($14,362 intro WAC)